What is elbasvir/grazoprevir?
Elbasvir/grazoprevir is anprescription medicine approved by the U.S. (FDA) for the treatment of chronic (HCV).
HCV is an What is an Opportunistic Infection? fact sheet.(OI) of HIV. An OI is an that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about OIs, read the HIVinfo
To learn how HIV and HCV are connected, read the HIVinfo HIV and Hepatitis C fact sheet. The fact sheet includes information about HCV , prevention, and treatment.
How is elbasvir/grazoprevir used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV reference the AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and TreatingC, which includes recommendations on the use of elbasvir/grazoprevir to treat HCV infection in people with HIV.
The recommended uses may not always be consistent with FDA-approved uses of elbasvir/grazoprevir. The above list may not include all of the HIV-related uses of elbasvir/grazoprevir recommended in the guidelines and the guidance. Some recommended uses, such as uses in certain rare circumstances, may have been omitted above.
What should I tell my health care provider before taking elbasvir/grazoprevir?
Before taking elbasvir/grazoprevir, tell your health care provider:
- If you are allergic to elbasvir, grazoprevir, or any other medicines.
- About any medical conditions you have or have had, especially (HBV) or problems other than HCV infection.
- If you have ever taken any medicine for HCV infection.
- If you have had or are waiting for a liver transplant.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
- If you are pregnant or plan to become pregnant. Whether elbasvir/grazoprevir can harm an unborn baby is unknown. Talk to your health care provider about the risks and benefits of taking elbasvir/grazoprevir during pregnancy. Sometimes elbasvir/grazoprevir is taken with the HCV medicine ribavirin. Ribavirin may cause birth defects or the death of an unborn baby. Do not take ribavirin if you are pregnant or your sexual partner is pregnant. You or your sexual partner should not become pregnant while taking ribavirin and for 6 months after the treatment ends.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Elbasvir/grazoprevir may affect the way other medicines or products work, and other medicines or products may affect how elbasvir/grazoprevir works. Ask your health care provider if there are interactions between elbasvir/grazoprevir and the other medicines you take.
Ask your health care provider about possible side effects from elbasvir/grazoprevir. Your health care provider will tell you what to do if you have side effects.
How should I take elbasvir/grazoprevir?
Take elbasvir/grazoprevir according to your health care provider’s instructions. Your health care provider will tell you how much elbasvir/grazoprevir to take and when to take it. Before you start elbasvir/grazoprevir and each time you get a refill, read any printed information that comes with your medicine.
How should elbasvir/grazoprevir be stored?
- Store elbasvir/grazoprevir at room temperature, 68°F to 77°F (20°C to 25°C).
- Keep elbasvir/grazoprevir in the container that it came in and keep the container tightly closed.
- Do not use elbasvir/grazoprevir if the original seal over the container opening is broken or missing.
- Throw away elbasvir/grazoprevir that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep elbasvir/grazoprevir and all medicines out of reach of children.
Where can I find more information about elbasvir/grazoprevir?
More information about elbasvir/grazoprevir is available:
- Recommendations on the HIV-related uses of elbasvir/grazoprevir, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, prepared by the , the , and the HIV Medicine Association of the Diseases Society of America
- Recommendations on the HIV-related uses of elbasvir/grazoprevir, from the AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, prepared by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America
- Elbasvir/grazoprevir-related research studies, from
The above Patient Version drug summary is based on the following FDA label(s): Tablet (film coated).
Last Reviewed: October 30, 2019